ETHOCELL
Osteoarthritic Knee Cartilage / Inflammatory Conditions
Pre-clinical/Early ClinicalActive
Key Facts
Indication
Osteoarthritic Knee Cartilage / Inflammatory Conditions
Phase
Pre-clinical/Early Clinical
Status
Active
Company
About Keli Therapeutics
KELI Therapeutics is a private, pre-revenue biotech founded in 2017 and headquartered in Kaunas, Lithuania, with a presence in Berlin. The company is developing a diversified pipeline of autologous and allogeneic cell therapies, primarily for cartilage repair and inflammatory diseases, with its lead programs in pre-clinical and early clinical development. It recently secured a €2.5 million grant from the European Innovation Council to fund a clinical trial in Acute Kidney Injury, indicating external validation and non-dilutive funding. Leadership comprises experienced professionals in regenerative medicine, manufacturing, and clinical development.
View full company profile